Table 1

Examples of overlap in scope between core outcome sets and matched guidance documents

Scenario*	Population	Intervention	Example title of COS	Example title of guidance document	Regulator
A	COS is narrower	COS is narrower	How to evaluate the clinical outcome of joint-preserving treatment for osteonecrosis of the femoral head: development of a core outcome set	Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis	EMA
B	COS is narrower	Exact match	None	None	N/A
C	COS is narrower	COS is broader	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type two diabetes	Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus	EMA
E	Exact match	COS is narrower	None	None	N/A
F	Exact match	Exact match	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis	Clinical development programmes for drugs, devices, and biological products for the treatment of rheumatoid arthritis	FDA
G	Exact match	COS is broader	Toward establishing core outcome domains for trials in kidney transplantation: report of the standardised outcomes in nephrology-kidney transplantation consensus workshops	Delayed graft function in kidney transplantation: developing drugs for prevention	FDA
I	COS is broader	COS is narrower	None	None	N/A
J	COS is broader	Exact match	None	None	N/A
K	COS is broader	COS is broader	Chronic rhinosinusitis outcome Measures (CHROME) – developing a core outcome set for trials of interventions in chronic rhinosinusitis	Non-allergic rhinitis: developing drug products for treatment	FDA

COS=core outcome set; EMA=European Medicines Agency; FDA=US Food and Drug Administration; N/A=not applicable.
*Letters relate to those in figure 1, top panel.